CA
NZ
UK
AU
IND
US
…
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cogent Biosciences is a clinical-stage biopharma developing targeted therapies for genetically defined cancers using biomarker-driven patient selection. Growth drivers include advancement of clinical programs to regulatory milestones, proof-of-concept data in selected indications, and potential partnerships. Investors may find it attractive because its precision oncology focus could support more efficient trials and clearer patient enrichment.
Most important risks are clinical and regulatory failure, intense competition in oncology, and financing risk from cash burn common to clinical-stage biotechs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
| Net income | -328.94M | -255.86M | -192.41M | -132.64M | -71.81M |
| Selling general administrative | 63.58M | 43.28M | 34.38M | 26.21M | 19.64M |
| Selling and marketing expenses | - | - | 34.34M | - | - |
| Gross profit | -4.62M | -4.40M | -3.59M | - | - |
| Reconciled depreciation | 4.58M | 4.35M | 3.73M | 5.88M | 0.15M |
| Ebit | -333.36M | -275.94M | -208.13M | -153.72M | -75.55M |
| Ebitda | -328.74M | -271.59M | -204.54M | -147.84M | -75.40M |
| Depreciation and amortization | 4.62M | 4.35M | 3.59M | 5.88M | 0.15M |
| Non operating income net other | - | - | - | 7.60M | 3.28M |
| Operating income | -333.36M | -275.94M | -208.13M | -147.84M | -75.55M |
| Other operating expenses | 333.36M | 275.94M | 208.13M | 147.84M | 75.55M |
| Interest expense | 3.06M | 0.00M | 0.00M | 3.99M | 3.13M |
| Interest income | 14.69M | 18.09M | 11.32M | 3.99M | 0.47M |
| Net interest income | 11.63M | 18.09M | 11.32M | 3.99M | 0.47M |
| Income tax expense | - | - | - | -7.60M | -0.47M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 328.74M | 275.94M | 208.13M | 147.84M | 75.55M |
| Cost of revenue | 4.62M | 4.40M | 3.59M | - | - |
| Total other income expense net | 4.43M | 20.08M | 15.72M | 7.60M | 3.28M |
| Net income from continuing ops | -328.94M | -255.86M | -177.66M | -140.24M | -72.27M |
| Net income applicable to common shares | - | - | - | -140.24M | -72.27M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M |
| Other current assets | 9.59M | 9.39M | 5.06M | 5.69M | 2.95M |
| Total liab | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M |
| Total stockholder equity | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M |
| Other current liab | 52.90M | 42.13M | 0.44M | 17.88M | 3.29M |
| Common stock | 0.16M | 0.11M | 0.09M | 0.07M | 0.04M |
| Capital stock | 89.55M | 110.71M | 60.12M | 65.90M | 85.44M |
| Retained earnings | -1188.42M | -859.48M | -603.62M | -411.21M | -270.97M |
| Other assets | - | - | - | 4.75M | 4.98M |
| Cash | 312.01M | 98.17M | 53.23M | 139.89M | 219.68M |
| Total current liabilities | 63.95M | 55.71M | 38.17M | 26.85M | 17.08M |
| Current deferred revenue | - | - | 25.69M | 1.70M | 7.97M |
| Net debt | -58.86M | -80.70M | -34.38M | -120.24M | -216.53M |
| Short term debt | 1.55M | 1.56M | 1.39M | 1.42M | 2.32M |
| Short long term debt total | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M |
| Other stockholder equity | 1734.88M | 1004.61M | 801.06M | 601.15M | 399.71M |
| Property plant equipment | - | - | - | 7.78M | 1.71M |
| Total current assets | 910.36M | 296.47M | 270.77M | 264.97M | 222.63M |
| Long term investments | - | 0.00M | 7.46M | - | - |
| Net tangible assets | - | - | - | 189.91M | 128.78M |
| Short term investments | 588.75M | 188.91M | 212.48M | 119.39M | - |
| Long term debt | 222.90M | - | - | - | - |
| Accounts payable | 9.50M | 12.01M | 10.65M | 5.84M | 3.48M |
| Accumulated other comprehensive income | 0.35M | 0.45M | 0.25M | -0.10M | - |
| Common stock total equity | - | - | - | 0.07M | 0.04M |
| Preferred stock total equity | - | - | - | 65.83M | 85.40M |
| Retained earnings total equity | - | - | - | -411.21M | -270.97M |
| Non currrent assets other | 3.72M | 4.86M | 4.86M | 4.75M | 4.98M |
| Non current assets total | 27.25M | 31.43M | 42.67M | 35.84M | 9.46M |
| Capital lease obligations | 15.90M | 17.47M | 18.85M | 19.65M | 3.15M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -397.97M | 38.28M | -79.90M | -117.86M | -1.72M |
| Change to liabilities | - | - | - | 11.95M | 6.18M |
| Total cashflows from investing activities | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M |
| Net borrowings | 217.76M | 0.00M | 0.00M | - | - |
| Total cash from financing activities | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M |
| Change to operating activities | - | - | - | -1.61M | -0.73M |
| Net income | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M |
| Change in cash | 214.26M | 44.94M | -87.91M | -79.80M | -22.51M |
| Begin period cash flow | 98.17M | 53.23M | 141.14M | 220.94M | 243.44M |
| End period cash flow | 312.43M | 98.17M | 53.23M | 141.14M | 220.94M |
| Total cash from operating activities | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M |
| Issuance of capital stock | 159.32M | 213.34M | 161.82M | 161.94M | 38.01M |
| Depreciation | 4.58M | 4.35M | 3.59M | 5.88M | 0.15M |
| Other cashflows from investing activities | - | 38.28M | - | - | - |
| Change to account receivables | - | - | - | - | 0.00M |
| Sale purchase of stock | - | - | - | 1.61M | 0.06M |
| Other cashflows from financing activities | -48.90M | 1.11M | 1.72M | 1.61M | -0.03M |
| Change to netincome | - | - | - | 18.37M | 11.69M |
| Capital expenditures | 1.55M | 0.57M | 2.80M | 6.86M | 1.72M |
| Cash flows other operating | - | - | - | -7.91M | -4.50M |
| Cash and cash equivalents changes | - | - | - | -79.80M | -22.51M |
| Change in working capital | 8.01M | 11.60M | 11.44M | 0.75M | 2.02M |
| Stock based compensation | 46.08M | 39.74M | 30.62M | 18.37M | 11.69M |
| Other non cash items | 5.82M | -7.62M | -6.87M | -3.39M | -0.34M |
| Free cash flow | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COGT Cogent Biosciences Inc |
-1.29 4.16% |
29.73 | - | - | 861.15 | 12.40 | 929.31 | -3.89 |
| NVO Novo Nordisk A/S |
0.45 1.12% |
40.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.73 1.03% |
553.15 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
33.37 3.60% |
961.26 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | Pres, CEO & Director | 1976 |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | NA |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 1975 |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 1980 |
| Mr. Brad Barnett | Chief Technology Officer | NA |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corp. Sec. | 1980 |
| Ms. Erin Schellhammer | Chief People Officer | NA |
| Ms. Sara Saltzman | Sr. VP of Regulatory Affairs | NA |
| Mr. Dana R. Martin Pharm.D. | Sr. VP of Medical Affairs & Chief Patient Officer | NA |
| Brad Fell | VP & Head of Medicinal Chemistry | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.08%
Communication Services
+0.23%
Consumer Cyclical
+1.15%
Consumer Defensive
+0.82%
Energy
-2.60%
Financial Services
+0.70%
Financials
+0.41%
Healthcare
-0.75%
Industrials
+0.32%
Real Estate
+0.57%
Technology
-1.16%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...